140 related articles for article (PubMed ID: 27140717)
1. Severe Myocardial Dysfunction Reversed by Iron-Chelation Therapy in an Asian Patient with Hereditary Hemochromatosis.
Kang Y; Chen XJ; Yu CP; You GY; Zhang Q
Am J Med Sci; 2016 May; 351(5):546-8. PubMed ID: 27140717
[No Abstract] [Full Text] [Related]
2. Case 25-2021: A 48-Year-Old Man with Fatigue and Leg Swelling.
Moore AB; Wing JR; Goiffon RJ; Leaf RK; Tsao L; Misdraji J
N Engl J Med; 2021 Aug; 385(8):745-754. PubMed ID: 34407347
[No Abstract] [Full Text] [Related]
3. An Iron-chelating Agent Improved the Cardiac Function in a Patient with Severe Heart Failure Due to Hereditary Hemochromatosis.
Setoguchi A; Kawano H; Okano S; Honda T; Kato T; Dateki S; Senoo A; Nakashima Y; Motokawa T; Ueno Y; Akashi R; Yonekura T; Sueyoshi E; Ikeda S; Miyazaki Y; Maemura K
Intern Med; 2024 Jan; 63(2):253-258. PubMed ID: 37197964
[TBL] [Abstract][Full Text] [Related]
4. [Heart failure in hemochromatosis. Apropos of a case].
Marty C; Elghozi D; Kulas A; Reboul M; Lainée J; Aubert P
Ann Med Interne (Paris); 1973; 124(6):507-11. PubMed ID: 4270967
[No Abstract] [Full Text] [Related]
5. Reversal of end-stage heart failure in juvenile hemochromatosis with iron chelation therapy: a case report.
Cooray SD; Heerasing NM; Selkrig LA; Subramaniam VN; Hamblin PS; McDonald CJ; McLean CA; McNamara E; Leet AS; Roberts SK
J Med Case Rep; 2018 Jan; 12(1):18. PubMed ID: 29373985
[TBL] [Abstract][Full Text] [Related]
6. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption.
Kontoghiorghes GJ; Spyrou A; Kolnagou A
Hemoglobin; 2010 Jun; 34(3):251-64. PubMed ID: 20524815
[TBL] [Abstract][Full Text] [Related]
7. Successful Treatment of Iron-Overload Cardiomyopathy in Hereditary Hemochromatosis With Deferoxamine and Deferiprone.
Tauchenová L; Křížová B; Kubánek M; Fraňková S; Melenovský V; Tintěra J; Kautznerová D; Malušková J; Jirsa M; Kautzner J
Can J Cardiol; 2016 Dec; 32(12):1574.e1-1574.e3. PubMed ID: 27789107
[TBL] [Abstract][Full Text] [Related]
8. Hemojuvelin hemochromatosis receiving iron chelation therapy with deferasirox: improvement of liver disease activity, cardiac and hematological function.
Maeda T; Nakamaki T; Saito B; Nakashima H; Ariizumi H; Yanagisawa K; Hattori A; Tatsumi Y; Hayashi H; Suzuki K; Tomoyasu S
Eur J Haematol; 2011 Nov; 87(5):467-9. PubMed ID: 21848699
[No Abstract] [Full Text] [Related]
9. Improvement in Left Ventricular Function Despite No Change in T2* with Iron Chelation in Secondary Hemochromatosis.
Nijjar PS; Vongooru H; Tamene A; Valeti U; Masri C
Minn Med; 2015 Jul; 98(7):47. PubMed ID: 26267924
[No Abstract] [Full Text] [Related]
10. Iron chelation therapy in hereditary hemochromatosis and thalassemia intermedia: regulatory and non regulatory mechanisms of increased iron absorption [Kontoghiorghes GJ, Spyrou A, Kolganou A. Hemoglobin. 2010;34(3); 251-264].
Nick HP
Hemoglobin; 2011; 35(2):175-9. PubMed ID: 21417578
[No Abstract] [Full Text] [Related]
11. [Myocardiopathy caused by iron deposition. Treatment with chelating agents].
Rodríguez Reguero JJ; Iglesias Cubero G; Espolita Santos A; López de la Iglesia JM; Enríquez Martín J; Tomás Mauri J; López-Negrete L
Rev Esp Cardiol; 1985; 38(5):356-7. PubMed ID: 4081244
[No Abstract] [Full Text] [Related]
12. Advances in the use of iron-chelating agents for the treatment of iron overload.
Modell B
Prog Hematol; 1979; 11():267-312. PubMed ID: 392593
[No Abstract] [Full Text] [Related]
13. Iron overload cardiomyopathy: from diagnosis to management.
Díez-López C; Comín-Colet J; González-Costello J
Curr Opin Cardiol; 2018 May; 33(3):334-340. PubMed ID: 29543671
[TBL] [Abstract][Full Text] [Related]
14. Iron chelation with deferasirox in two patients with HFE hemochromatosis and chronic anemia.
Nagler M; Gregor M; Wuillemin WA
Acta Haematol; 2011; 126(2):119-21. PubMed ID: 21659727
[TBL] [Abstract][Full Text] [Related]
15. [A case of hereditary hemochromatosis with predominant involvement of the heart].
Enikeeva NB; Shcherbinina SP; Tarasov VK; Savel'eva TV; Moiseev SV; Severov MV; Levina AA; Klinova EG; Nushtaeva NN; Anikina TP
Ter Arkh; 1991; 63(4):137-9. PubMed ID: 2068666
[No Abstract] [Full Text] [Related]
16. Comparing Care of the Primary and Secondary Hemochromatosis Patients.
Becker S
J Infus Nurs; 2020; 43(2):65-69. PubMed ID: 32106193
[TBL] [Abstract][Full Text] [Related]
17. Deferasirox in patients with iron overload secondary to hereditary hemochromatosis: results of a 1-yr Phase 2 study.
Cançado R; Melo MR; de Moraes Bastos R; Santos PC; Guerra-Shinohara EM; Chiattone C; Ballas SK
Eur J Haematol; 2015 Dec; 95(6):545-50. PubMed ID: 25684349
[TBL] [Abstract][Full Text] [Related]
18. Cardiac Hemochromatosis Treated With Prolonged Extracorporeal Membrane Oxygenation Support and Chelation Therapy.
Lee JA; Tchantchaleishvili V; Vidula H
Artif Organs; 2018 May; 42(5):575-576. PubMed ID: 29878536
[No Abstract] [Full Text] [Related]
19. Iron chelation.
Chandy M
J Assoc Physicians India; 1991 Sep; 39(9):665-6. PubMed ID: 1814896
[No Abstract] [Full Text] [Related]
20. Histological changes in cardiac hemochromatosis improved by an iron-chelating agent. A biopsy case.
Tashiro A; Satodate R; Segawa I
Acta Pathol Jpn; 1990 Apr; 40(4):288-92. PubMed ID: 2371834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
